Adjuvant chemotherapy of breast cancer

Richard G. Cooper, James F. Holland, Oliver Glidewell

Research output: Contribution to journalArticlepeer-review

79 Scopus citations


One hundred women with primary breast cancer with 4 or more metastatic axillary nodes were treated for 9 months postoperatively with vincristine, prednisone, cyclophosphamide, methotrexate, and fluorouracil (VPCMF). Sixty‐five women have been observed for a minimum of 5 years or until failure and the rest for 3 years or more. For 73 women who received adjuvant chemotherapy only, observed for 5 1/2 years median, disease‐free status by life table analysis is 68% at 8 years. No significant difference was found between response of pre‐ and postmenopausal women in disease‐free interval or survival. Mortality compared to expectation was sharply reduced; only 9 of 73 have died. These findings demonstrate the long term effectiveness of relatively short‐term surgical adjuvant combination chemotherapy in pre‐ and postmenopausal patients with breast cancer at righ risk.

Original languageEnglish
Pages (from-to)793-798
Number of pages6
Issue number3
StatePublished - Sep 1979
Externally publishedYes


Dive into the research topics of 'Adjuvant chemotherapy of breast cancer'. Together they form a unique fingerprint.

Cite this